Ticker >

Aurobindo Pharma share price

Aurobindo Pharma Ltd.

NSE: AUROPHARMA BSE: 524804 SECTOR: Pharmaceuticals & Drugs  201k   1k   276

1353.20
-4.20 (-0.31%)
BSE: 24 Jul 04:01 PM

Price Summary

Today's High

₹ 1365.85

Today's Low

₹ 1347.75

52 Week High

₹ 1409.25

52 Week Low

₹ 785.7

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

79289.21 Cr.

Enterprise Value

83299.64 Cr.

No. of Shares

58.59 Cr.

P/E

41.73

P/B

4.02

Face Value

₹ 1

Div. Yield

0.22 %

Book Value (TTM)

₹  336.6

CASH

132.14 Cr.

DEBT

4142.57 Cr.

Promoter Holding

51.8 %

EPS (TTM)

₹  32.43

Sales Growth

13.33%

ROE

7.02 %

ROCE

8.44%

Profit Growth

-15.42 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Aurobindo Pharma Ltd.

Molnaflu Imdur Betaloc Seloken Ramace Plendil RHINOCORT Prostodin MERONEM XyloCaine SensorCaine Iressa Casodex CRESTOR

Index Presence

The company is present in 26 Indices.

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year13.33%
3 Year-1.46%
5 Year4.49%

Profit Growth

1 Year-15.42%
3 Year-13.13%
5 Year-7.46%

ROE%

1 Year7.02%
3 Year12.44%
5 Year13.41%

ROCE %

1 Year8.44%
3 Year13.33%
5 Year14.17%

Debt/Equity

0.2312

Price to Cash Flow

43.54

Interest Cover Ratio

15.0402678726735

CFO/PAT (5 Yr. Avg.)

1.22478119730918

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2024 51.8 20.88
Mar 2024 51.83 20.86
Dec 2023 51.83 18.9
Sep 2023 51.83 19.56
Jun 2023 51.83 19.16
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has a healthy Interest coverage ratio of 15.0402678726735.
  • The company has a good cash flow management; CFO/PAT stands at 1.22478119730918.

 Limitations

  • The company has shown a poor profit growth of -13.1297412263747% for the Past 3 years.
  • The company has shown a poor revenue growth of -1.46347472841358% for the Past 3 years.
  • Promoter pledging is high as 20.88%.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
Net Sales 2406.23 2390.82 2668.76 2692.03 2894.03
Total Expenditure 1830.31 1968.44 2123.58 2210.34 2119.24
Operating Profit 575.92 422.38 545.18 481.69 774.79
Other Income 280.19 94.88 67.08 331.13 122.97
Interest 31.77 31.59 36.69 61.25 53.07
Depreciation 66.68 59.63 65.79 64.35 64.81
Exceptional Items 0 0 0 0 0
Profit Before Tax 757.66 426.04 509.78 687.22 779.88
Tax 158.98 108.04 130.13 63.44 201.21
Profit After Tax 598.68 318 379.65 623.78 578.67
Adjusted EPS (Rs) 10.22 5.43 6.48 10.65 9.88

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 12257.89 13370.77 15823.68 11287.14 12792.28
Total Expenditure 9848.6 10672.9 11703.85 9831.6 11061.36
Operating Profit 2409.29 2697.87 4119.83 1455.54 1730.92
Other Income 199.22 388.79 589.86 688.85 433.76
Interest 230.86 243.28 28.68 16.94 114.98
Depreciation 413.03 473.33 488 415.26 435.35
Exceptional Items 0 0 0 -74.71 0
Profit Before Tax 1964.62 2370.05 4193.01 1637.48 1614.35
Tax 434.89 493.17 1080.1 182.77 383.94
Net Profit 1529.73 1876.88 3112.91 1454.71 1230.41
Adjusted EPS (Rs.) 26.11 32.03 53.13 24.83 21

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 58.59 58.59 58.59 58.59 58.59
Total Reserves 11292.03 12993.91 15866.02 17058.75 17855.58
Borrowings 0 0 0 0 0
Other N/C liabilities 53.64 138.86 1412.13 4566.44 3138.49
Current liabilities 6736.46 6372.25 6756.58 4180.97 6987.94
Total Liabilities 18140.72 19563.61 24093.32 25864.75 28040.6
Assets
Net Block 4149.7 4417.8 4472.07 3585.83 3687.5
Capital WIP 750.07 814.85 719.02 225.15 239.09
Intangible WIP 38.94 0 15.87 0 0
Investments 2339.04 2527.39 4880.89 6584.35 8221.77
Loans & Advances 402.93 444.9 1610.41 5605.43 5800.23
Other N/C Assets 51.7 70.37 59.05 28.88 53.78
Current Assets 10408.34 11288.3 12336.01 9835.11 10038.23
Total Assets 18140.72 19563.61 24093.32 25864.75 28040.6
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 1964.62 2370.05 4193.01 1637.48 1614.35
Adjustment 458.99 414.2 53.15 -30.65 175.19
Changes in Assets & Liabilities -1411.6 -204.18 -624.78 2811.95 332.21
Tax Paid -482.12 -378.69 -626.85 -692.07 -300.59
Operating Cash Flow 529.89 2201.38 2994.53 3726.71 1821.16
Investing Cash Flow -1300.54 -948.08 -2650.24 -1614.54 -3459.2
Financing Cash Flow 599.4 -1254.65 -28.06 -2447.54 1719.48
Net Cash Flow -171.25 -1.35 316.23 -335.37 81.44

Corporate Actions

Investors Details

PARTICULARS Jun 2023% Sep 2023% Dec 2023% Mar 2024% Jun 2024%
promoters 51.83 51.83 51.83 51.83 51.80
axis clinicals limited 0.11 0.11 0.11 0.11 0.11
axis clinicals limited, t... 2.85 2.85 2.85 2.85 2.85
k nityananda reddy 4.33 4.33 4.33 4.33 4.33
kambam spoorthi 1.19 1.19 1.19 1.19 1.19
kirthi reddy kambam 3.49 3.49 3.49 3.49 3.46
m sivakumaran 2.47 2.47 2.47 2.47 2.47
m sumanth kumar reddy 0.27 0.27 0.27 0.27 0.27
prasada reddy kambham 0.05 0.05 0.05 0.05 0.05
rajeshwari kambam 0.31 0.31 0.31 0.31 0.31
rpr sons advisors private... 33.51 33.51 33.51 33.51 33.51
suneela rani penaka 0.02 0.02 0.02 0.02 0.02
trident chemphar limited 0.13 0.13 0.13 0.13 0.13
venkata ramprasad reddy p... 3.07 3.07 3.07 3.07 3.07
PARTICULARS Jun 2023% Sep 2023% Dec 2023% Mar 2024% Jun 2024%
investors 48.17 48.17 48.17 48.17 48.20
hdfc mutual fund-hdfc arb... - - - - 4.34
icici prudential regular ... - - - - 4.20
investor education and pr... - - 0.14 - 0.14
life insurance corporatio... 5.55 5.43 3.81 3.38 2.78
mirae asset nifty 200 alp... - - - - 2.69
quant mutual fund - quant... - - - - 3.27
hdfc mutual fund - - - 3.78 -
icici prudential mutual f... - - - 3.60 -
investor education and pr... 0.14 0.14 - 0.14 -
mirae asset large cap fun... - - - 2.84 -
quant mutual fund - - - 2.54 -
bnp paribas financial mar... - - 1.62 - -
hdfc mutual fund - hdfc s... - 3.65 4.40 - -
icici prudential midcap f... - - 1.18 - -
mirae asset elss tax save... - - 1.78 - -
quant mutual fund-quant e... - - 2.20 - -
bnp paribas arbitrage 1.24 1.41 - - -
mirae asset equity saving... - 1.65 - - -
quant mutual fund-quant t... - 1.80 - - -
hdfc mutual fund - hdfc m... 3.06 - - - -
invesco asian equity inco... 1.12 - - - -
mirae asset tax saver fun... 1.33 - - - -
quant mutual fund - quant... 1.46 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Aurobindo Pharma’s step-down arm acquires entire stake in Ace Laboratories29 Jun 2024, 2:10PM Aurobindo Pharma’s arm step-down gets Establishment Inspection Report for Telangana injectable facility27 Jun 2024, 2:56PM Aurobindo Pharma informs about loss of shares certificate12 Jun 2024, 11:51AM Aurobindo Pharma informs about analyst meet 6 Jun 2024, 12:55PM Aurobindo Pharma’s arm inks pact with MSD3 Jun 2024, 4:30PM Aurobindo Pharma informs about newspaper publication27 May 2024, 12:56PM Aurobindo Pharma reports 79% rise in Q4 consolidated net profit27 May 2024, 11:22AM Aurobindo Pharma’s arm’s manufacturing unit gets 'official action indicated' status by USFDA 27 May 2024, 10:00AM Aurobindo Pharma - Quaterly Results25 May 2024, 7:01PM Aurobindo Pharma - Quaterly Results25 May 2024, 7:01PM Aurobindo Pharma - Quaterly Results25 May 2024, 7:01PM USFDA concludes inspection at Unit-VII of Aurobindo Pharma’s arm in Andhra Pradesh10 May 2024, 5:41PM USFDA concludes inspection at Unit-II of Aurobindo Pharma’s arm in Rajasthan3 May 2024, 6:02PM Aurobindo Pharma informs about disclosure 2 May 2024, 10:55AM Aurobindo Pharma informs about details of loss of certificate 22 Apr 2024, 4:04PM Aurobindo Pharma informs about issuance of letter(s) of confirmation8 Apr 2024, 3:59PM USFDA concludes inspection at Andhra Pradesh facility of Aurobindo Pharma’s arm 5 Apr 2024, 5:15PM Aurobindo Pharma informs about disclosure with respect to non-applicability of large corporate 5 Apr 2024, 4:59PM Aurobindo Pharma informs about disclosure 3 Apr 2024, 2:21PM Aurobindo Pharma gets final nod to manufacture, market Mometasone Furoate Monohydrate Nasal Spray20 Mar 2024, 9:41AM Aurobindo Pharma’s arm restarts distribution of aseptic products manufactured at Unit III13 Mar 2024, 11:08AM Aurobindo Pharma informs about media meet 6 Mar 2024, 2:42PM Aurobindo Pharma gets final nod to manufacture, market Fingolimod Capsules, 0.5 mg 2 Mar 2024, 9:57AM USFDA concludes inspection at injectable facility of Aurobindo Pharma’s arm1 Mar 2024, 12:30PM Aurobindo Pharma informs about disclosure29 Feb 2024, 11:00AM Aurobindo Pharma informs about press release23 Feb 2024, 2:54PM USFDA concludes inspection at synthetic peptide API facility of Aurobindo Pharma’s arm16 Feb 2024, 2:30PM Aurobindo Pharma gets USFDA’s final nod for Deflazacort Tablets12 Feb 2024, 3:41PM Aurobindo Pharma reports 91% rise in Q3 consolidated net profit12 Feb 2024, 2:50PM Aurobindo Pharma - Quaterly Results10 Feb 2024, 5:41PM Aurobindo Pharma - Quaterly Results10 Feb 2024, 5:41PM Aurobindo Pharma - Quaterly Results10 Feb 2024, 5:41PM Aurobindo Pharma informs about record date7 Feb 2024, 2:19PM Aurobindo Pharma informs about record date for payment of second interim dividend7 Feb 2024, 1:09PM Aurobindo Pharma informs about updates5 Feb 2024, 1:32PM Aurobindo Pharma gets Establishment Inspection Report for Telangana facility 9 Jan 2024, 2:35PM Aurobindo Pharma's arm gets USFDA's approval for Posaconazole Injection27 Dec 2023, 11:59AM USFDA conducts Pre-Approval Inspection at injectable facility of Aurobindo Pharma’s arm26 Dec 2023, 11:44AM Aurobindo Pharma informs about loss of share certificates21 Dec 2023, 4:36PM Aurobindo Pharma informs about updates20 Dec 2023, 2:50PM Aurobindo Pharma gets EIR for Andhra Pradesh manufacturing facility20 Dec 2023, 2:30PM Aurobindo Pharma informs about completion of acquisition 15 Dec 2023, 2:18PM Aurobindo Pharma informs about issuance of letter of confirmations8 Dec 2023, 5:29PM Aurobindo Pharma informs about press release30 Nov 2023, 2:43PM Aurobindo Pharma’s arm gets USFDA’s final nod for Budesonide Inhalation Suspension30 Nov 2023, 12:14PM Aurobindo Pharma informs about press release29 Nov 2023, 3:34PM Aurobindo Pharma gets USFDA’s final nod for Darunavir Tablets29 Nov 2023, 12:14PM Aurobindo Pharma informs about issue of duplicate share certificate28 Nov 2023, 2:27PM Aurobindo Pharma informs about newspaper publication25 Nov 2023, 11:30AM Aurobindo Pharma incorporates wholly owned subsidiary22 Nov 2023, 2:10PM

Aurobindo Pharma Stock Price Analysis and Quick Research Report. Is Aurobindo Pharma an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Aurobindo Pharma and its performance over the period of time. Aurobindo Pharma stock price today is Rs 1353.7.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Aurobindo Pharma cash from the operating activity was Rs 1821.16 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Aurobindo Pharma has a Debt to Equity ratio of 0.2312 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Aurobindo Pharma , the EPS growth was -15.4189120610908 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Aurobindo Pharma has OPM of 13.5309733683128 % which is a bad sign for profitability.
     
  • ROE: Aurobindo Pharma have a poor ROE of 7.02459014755573 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Aurobindo Pharma is Rs 1353.7. One can use valuation calculators of ticker to know if Aurobindo Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about Aurobindo Pharma

Aurobindo Pharma Ltd. Financials: Check Share Price, Balance Sheet, Annual Report and Quarterly Results for Company Analysis

Welcome to our Aurobindo Pharma Ltd. stock analysis page, where long-term stock investors can find a comprehensive range of resources and tools to make well-informed investment decisions. Our platform offers an in-depth analysis of various aspects of Aurobindo Pharma's stock performance, allowing investors to gain valuable insights into the company's financial stability, growth potential, and viability as a long-term investment. Let's delve into each topic in detail.

Aurobindo Pharma Ltd. Share Price Analysis

Analyzing the share price of Aurobindo Pharma Ltd. is crucial for understanding the company's growth potential and market sentiment. Our pre-built screening tools enable investors to track the historical share price of the company over different timeframes. By studying price trends, trading volumes, trading range, and the stock's relative performance compared to market indices, investors gain insights into Aurobindo Pharma's financial stability, growth prospects, and viability as a long-term investment. For a more comprehensive analysis, investors can leverage our premium features tools, such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis, to evaluate the stock's intrinsic value and growth potential.

Aurobindo Pharma Ltd. Balance Sheet Evaluation

Evaluating the balance sheet of Aurobindo Pharma Ltd. is a critical step for long-term investors to understand the company's financial position and growth potential. Our pre-built screening tools enable investors to determine Aurobindo Pharma's balance sheet ratios and metrics. By examining key financial indicators, such as current assets, current liabilities, and long-term debt, investors gain insights into the company's financial stability, liquidity, and potential for growth. Our premium features tools, including DCF Analysis, BVPS Analysis, Earnings multiple approaches, and DuPont analysis, provide a more comprehensive analysis of Aurobindo Pharma's balance sheet, helping investors assess its long-term investment potential.

Aurobindo Pharma Ltd. Annual Report Insights

Aurobindo Pharma Ltd.'s annual reports offer a wealth of information about the company's performance, strategies, and plans. On our platform, you can access downloadable PDF versions of Aurobindo Pharma's annual reports, along with expert reviews and analysis. These annual reports provide insights into Aurobindo Pharma's business model, competitive landscape, and macroeconomic factors that may impact its operations. Coupled with our premium features tools, investors can conduct a thorough analysis and make well-informed decisions based on Aurobindo Pharma's annual report.

Aurobindo Pharma Ltd. Dividend Payments

Analyzing Aurobindo Pharma Ltd.'s dividend payments is crucial for long-term investors seeking stable returns. Our stock analysis page provides comprehensive data on the company's dividend payment history. By analyzing Aurobindo Pharma's profitability, dividend policy, and metrics such as the dividend yield and payout ratio, investors can make well-informed investment decisions. Our premium features tools, including DCF Analysis, BVPS Analysis, Earnings multiple approaches, and DuPont analysis, allow investors to evaluate the impact of dividends on Aurobindo Pharma's stock value and overall investment strategy.

Aurobindo Pharma Ltd. Quarterly Results Analysis

Analyzing Aurobindo Pharma Ltd.'s quarterly results helps investors evaluate its short-term performance and gauge its future growth potential. On our website, you can find downloadable PDF files of Aurobindo Pharma's quarterly results, allowing investors to assess the company's recent performance and key financial metrics, such as revenue growth, earnings per share, and margins. By leveraging our premium features tools and conducting a thorough analysis, long-term investors can make well-informed decisions regarding their investment positions in Aurobindo Pharma.

Aurobindo Pharma Ltd. Stock Price Trends

Analyzing Aurobindo Pharma Ltd.'s stock price trends is essential for understanding its growth potential and market sentiment. Our pre-built screening tools enable investors to track Aurobindo Pharma's stock price trends over different timeframes. This allows the identification of short-term and long-term patterns and pricing volatility. By utilizing our premium features tools, investors gain additional insights into factors affecting Aurobindo Pharma's stock performance, aiding them in making well-informed decisions about their long-term investment positions.

Aurobindo Pharma Ltd. Price Charts

Technical analysis through price chart analysis provides additional insights into Aurobindo Pharma Ltd.'s stock performance. On our website, you can access dynamic price charts that display historical price movements, technical indicators, and patterns. These charts assist investors in identifying potential entry and exit points, support and resistance levels, and trend reversals. By incorporating these insights into our premium features tools, investors can conduct a comprehensive analysis and make informed decisions about Aurobindo Pharma as a long-term investment.

Aurobindo Pharma Ltd. News Updates

Keeping up with the latest news and developments concerning Aurobindo Pharma Ltd. is fundamental for long-term investors. Our website provides comprehensive and timely information sourced from reliable news channels. Through articles and news updates, investors gain insights into Aurobindo Pharma's industry trends, market position, and future outlook. This information empowers investors to make well-informed decisions and stay ahead of market dynamics affecting their long-term investment positions in Aurobindo Pharma.

Aurobindo Pharma Ltd. Conference Calls

Aurobindo Pharma Ltd.'s conference calls offer crucial insights into the company's operations, financial performance, and growth strategies. On our platform, you can find a searchable collection of Aurobindo Pharma's conference calls, including downloadable recordings. By listening to these calls, investors gain a deep understanding of Aurobindo Pharma's management team, growth plans, and economic factors impacting the company's performance. Leveraging our premium features tools, investors can carry out comprehensive analyses and make well-informed decisions regarding their long-term investment positions in Aurobindo Pharma.

Aurobindo Pharma Ltd. Transcripts

Transcripts of Aurobindo Pharma Ltd.'s conference calls capture important discussions and insights. Our platform provides downloadable transcripts that include in-depth analyses of the company's financial performance, future plans, and market trends. Reviewing these transcripts offers valuable insights into Aurobindo Pharma's strategies, growth potential, and adaptability to market dynamics. By leveraging our premium features tools and conducting a comprehensive analysis, investors can make well-informed decisions about Aurobindo Pharma as a long-term investment.

Aurobindo Pharma Ltd. Investor Presentations

Aurobindo Pharma Ltd.'s investor presentations offer detailed information about the company's financials, strategic initiatives, and future plans. On our platform, you can easily access these investor presentations in downloadable PDF format. Investor presentations provide insights beyond the numbers, delving deep into Aurobindo Pharma's growth strategy, market expansion plans, and competitive advantages. By leveraging our premium features tools and pre-built screening tools, investors can perform a comprehensive analysis of Aurobindo Pharma and make sound investment decisions.

Aurobindo Pharma Ltd. Promoters and Shareholders

Understanding the ownership structure of Aurobindo Pharma Ltd. is crucial for long-term investors evaluating the company's growth potential and stability. Our pre-built screening tools enable investors to assess promoter holdings and analyze the company's shareholder base. By understanding the distribution of ownership and the alignment of interests, investors can make well-informed decisions about their long-term investment positions in Aurobindo Pharma.

Aurobindo Pharma Ltd. ROCE

The Return on Capital Employed (ROCE) is a key financial metric used to assess the profitability and efficiency of a company. It measures how effectively a company utilizes its capital to generate profits. By analyzing Aurobindo Pharma Ltd.'s ROCE, investors can evaluate the company's ability to generate returns from the capital employed in its operations. ROCE is calculated by dividing the operating profit by the capital employed. The ratio's data can be found in the financials table or ratio section on this page.

Aurobindo Pharma Ltd. EBITDA

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It provides a clearer picture of a company's operating performance by excluding non-operating expenses. Aurobindo Pharma Ltd.'s EBITDA serves as a useful measure to assess the company's profitability and cash flow generation. It helps investors understand the core earnings potential of the company's operations. The EBITDA data for Aurobindo Pharma Ltd. can be found in the financials table or ratio section on this page.

Aurobindo Pharma Ltd. DPS

DPS stands for Dividends Per Share, which is one of the key indicators of shareholder returns. Aurobindo Pharma Ltd.'s DPS reflects the amount of dividends distributed to shareholders per outstanding share. Investors often consider the DPS when assessing the company's dividend policy and its commitment to returning value to shareholders. The DPS data for Aurobindo Pharma Ltd. can be found in the financials table or ratio section on this page.

Aurobindo Pharma Ltd. EPS

EPS, or Earnings Per Share, is an important measure of a company's profitability and its ability to generate earnings for each outstanding share. Aurobindo Pharma Ltd.'s EPS provides insights into the company's net profits on a per-share basis. Investors often use EPS to compare companies within the same industry or to understand the company's growth potential. The EPS data for Aurobindo Pharma Ltd. can be found in the financials table or ratio section on this page.

Read More
X